[HTML][HTML] Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
YX Wu, JH Yang, H Saitsu - Oncotarget, 2016 - ncbi.nlm.nih.gov
Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
YX Wu, JH Yang, H Saitsu - Oncotarget, 2016 - pubmed.ncbi.nlm.nih.gov
Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
[HTML][HTML] Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
YX Wu, JH Yang, H Saitsu - Oncotarget, 2016 - oncotarget.com
Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
[PDF][PDF] Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
YX Wu, JH Yang, H Saitsu - pdfs.semanticscholar.org
Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance.
YX Wu, JH Yang, H Saitsu - Oncotarget, 2016 - europepmc.org
Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
[引用][C] Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
YX Wu, JH Yang, H Saitsu - Oncotarget, 2016 - cir.nii.ac.jp
Bortezomib-resistance is associated with increased levels of proteasome subunits and
apoptosis-avoidance | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
apoptosis-avoidance | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
YX Wu, JH Yang, H Saitsu - Oncotarget, 2016 - oncotarget.com
Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …